Closing the translational gap between mutant mouse models and the clinical reality of psychotic illness

Neuroscience and Biobehavioral Reviews

Volumn 58, Issue , 2015, Pages 19-35

  O'Tuathaigh, Colm M ^a   Waddington, John L ^b,c  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c SOOCHOW UNIVERSITY   (China)

Author keywords

Gene environment interactions; Gene Gene interactions; Mutant mouse models; Mutant phenotype; Psychosis; Schizophrenia

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MICRORNA; MICRORNA 137; NEUROGRANIN; UNCLASSIFIED DRUG;

CACNA1C GENE; DEVELOPMENTAL DISORDER; DISC1 GENE; DRD2 GENE; EPISTASIS; GENE INTERACTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE ENVIRONMENT INTERACTION; GRIA1 GENE; GRIN2A GENE; GRM3 GENE; HERITABILITY; HUMAN; MHC GENE; MOUSE; MOUSE MUTANT; NLGN4 GENE; NONHUMAN; NRGN GENE; NRXN1 GENE; PHENOTYPE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SRR GENE; ANIMAL; DISEASE MODEL; GENETICS; MUTATION; TRANSGENIC MOUSE; TRANSLATIONAL RESEARCH;

ANIMALS; DISEASE MODELS, ANIMAL; GENE-ENVIRONMENT INTERACTION; HUMANS; MICE; MICE, TRANSGENIC; MUTATION; PSYCHOTIC DISORDERS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84949538695     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2015.01.016     Document Type: Review

References (223)

1. Abazyan B., Nomura J., Kannan G., Ishizuka K., Tamashiro K.L., Nucifora F., Pogorelov V., Ladenheim B., Yang C., Krasnova I.N., Cadet J.L., Pardo C., Mori S., Kamiya A., Vogel M.W., Sawa A., Ross C.A., Pletnikov M.V. Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology. Biol. Psychiatry 2010, 68:1172-1181.
2. Agid O., Siu C.O., Potkin S.G., Kapur S., Watsky E., Vanderburg D., Zipursky R.B., Remington G. Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010. Am. J. Psychiatry 2013, 170:1335-1344.
3. Allen K., Gil M., Resnik E., Toader O., Seeburg P., Monyer H. Impaired path integration and grid cell spatial periodicity in mice lacking GluA1-containing AMPA receptors. J. Neurosci. 2014, 34:6245-6259.
4. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington, DC. 4th ed.
5. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2013, American Psychiatric Association, Washington, DC. 5th ed.
6. Arnedo J., Svrakic D.M., Del Val C., Romero-Zaliz R., Hernández-Cuervo H., Molecular Genetics of Schizophrenia Consortium, Fanous A.H., Pato M.T., Pato C.N., de Erausquin G.A., Cloninger C.R., Zwir I. Uncovering the hidden risk architecture of the schizophrenias: confirmation in three independent genome-wide association studies. Am. J. Psychiatry 2014, 10.1176/appi.ajp.2014.14040435.
7. Balu D.T., Li Y., Puhl M.D., Benneyworth M.A., Basu A.C., Takagi S., Bolshakov V.Y., Coyle J.T. Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E2400-E2409.
8. Bannerman D.M., Niewoehner B., Lyon L., Romberg C., Schmitt W.B., Taylor A., Sanderson D.J., Cottam J., Sprengel R., Seeburg P.H., Köhr G., Rawlins J.N. NMDA receptor subunit NR2A is required for rapidly acquired spatial working memory but not incremental spatial reference memory. J. Neurosci. 2008, 28:3623-3630.
9. Barak S., Weiner I. Putative cognitive enhancers in preclinical models related to schizophrenia: the search for an elusive target. Pharmacol. Biochem. Behav. 2011, 99:164-189.
10. Barkus C., Feyder M., Graybeal C., Wright T., Wiedholz L., Izquierdo A., Kiselycznyk C., Schmitt W., Sanderson D.J., Rawlins J.N., Saksida L.M., Bussey T.J., Sprengel R., Bannerman D., Holmes A. Do GluA1 knockout mice exhibit behavioral abnormalities relevant to the negative or cognitive symptoms of schizophrenia and schizoaffective disorder?. Neuropharmacology 2012, 62:1263-1272.
11. Barkus C., Sanderson D.J., Rawlins J.N., Walton M.E., Harrison P.J., Bannerman D.M. What causes aberrant salience in schizophrenia? A role for impaired short-term habituation and the GRIA1 (GluA1) AMPA receptor subunit. Mol. Psychiatry 2014, 19:1060-1070.
12. Bartko S.J., Romberg C., White B. Intact attentional processing but abnormal responding in M1 muscarinic receptor-deficient mice using an automated touchscreen method. Neuropharmacology 2011, 61:1366-1378.
13. Basu A.C., Tsai G.E., Ma C.L., Ehmsen J.T., Mustafa A.K., Han L., Jiang Z.I., Benneyworth M.A., Froimowitz M.P., Lange N., Snyder S.H., Bergeron R., Coyle J.T. Targeted disruption of serine racemase affects glutamatergic neurotransmission and behaviour. Mol. Psychiatry 2009, 14:719-727.
14. Behan A.T., Hryniewiecka M., O'Tuathaigh C.M., Kinsella A., Cannon M., Karayiorgou M., Gogos J.A., Waddington J.L., Cotter D.R. Chronic adolescent exposure to delta-9-tetrahydrocannabinol in COMT mutant mice: impact on indices of dopaminergic, endocannabinoid and GABAergic pathways. Neuropsychopharmacology 2012, 37:1773-1783.
15. Belforte J.E., Zsiros V., Sklar E.R., Jiang Z., Yu G., Li Y., Quinlan E.M., Nakazawa K. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat. Neurosci. 2010, 13:76-83.
16. Bendikov I., Nadri C., Amar S., Panizzutti R., De Miranda J., Wolosker H., Agam G. A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia. Schizophr. Res. 2007, 90:41-51.
17. Benneyworth M.A., Basu A.C., Coyle J.T. Discordant behavioral effects of psychotomimetic drugs in mice with altered NMDA receptor function. Psychopharmacology (Berl.) 2011, 213:143-153.
18. Bishop J.R., Reilly J.L., Harris M.S., Patel S.R., Kittles R., Badner J.A., Prasad K.M., Nimgaonkar V.L., Keshavan M.S., Sweeney J.A. Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia. Psychopharmacology (Berl.) 2014, [Epub ahead of print].
19. Blackwood D.H., Fordyce A., Walker M.T., St Clair D.M., Porteous D.J., Muir W.J. Schizophrenia and affective disorders - cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am. J. Hum. Genet. 2001, 69:428-433.
20. Braff D.L., Geyer M.A., Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl.) 2001, 156:234-258.
21. Brandon N.J., Sawa A. Linking neurodevelopmental and synaptic theories of mental illness through DISC1. Nat. Rev. Neurosci. 2011, 12:707-722.
22. Brown A.S. The environment and susceptibility to schizophrenia. Prog. Neurobiol. 2011, 93:23-58.
23. Bussey T.J., Holmes A., Lyon L., Mar A.C., McAllister K.A., Nithianantharajah J., Oomen C.A., Saksida L.M. New translational assays for preclinical modelling of cognition in schizophrenia: the touchscreen testing method for mice and rats. Neuropharmacology 2011, 62:1191-1203.
24. Camargo L.M., Collura V., Rain J.C., Mizuguchi K., Hermjakob H., Kerrien S., Bonnert T.P., Whiting P.J., Brandon N.J. Disrupted in schizophrenia 1 interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. Mol. Psychiatry 2007, 12:74-86.
25. Carpenter W.T. The facts of schizophrenia: a personal commentary. Schizophr. Res. 2011, 128:3-4.
26. Cartmell J., Schoepp D.D. Regulation of neurotransmitter release by metabotropic glutamate receptors. J. Neurochem. 2000, 75:889-907.
27. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., Taylor A., Arseneault L., Williams B., Braithwaite A., Poulton R., Craig I.W. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene×environment interaction. Biol. Psychiatry 2005, 57:1117-1127.
28. Chohan T.W., Boucher A.A., Spencer J.R., Kassem M.S., Hamdi A.A., Karl T., Fok S.Y., Bennett M.R., Arnold J.C. Partial genetic deletion of neuregulin 1 modulates the effects of stress on sensorimotor gating, dendritic morphology, and HPA axis activity in adolescent mice. Schizophr. Bull. 2014, 40:1272-1284.
29. Chourbaji S., Vogt M.A., Fumagalli F., Sohr R., Frasca A., Brandwein C., Hörtnagl H., Riva M.A., Sprengel R., Gass P. AMPA receptor subunit 1 (GluR-A) knockout mice model the glutamate hypothesis of depression. FASEB J. 2008, 22:3129-3134.
30. Clapcote S.J., Lipina T.V., Millar J.K., Mackie S., Christie S., Ogawa F., Lerch J.P., Trimble K., Uchiyama M., Sakuraba Y., Kaneda H., Shiroishi T., Houslay M.D., Henkelman R.M., Sled J.G., Gondo Y., Porteous D.J., Roder J.C. Behavioral phenotypes of Disc1 missense mutations in mice. Neuron 2007, 54:387-402.
31. Cross-Disorder Group of the Psychiatric Genomics Consortium Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat. Genet. 2013, 45:984-994.
32. Crowley J.J., Collins A.L., Lee R.J., Nonneman R.J., Farrell M.S., Ancalade N., Mugford J.W., Agster K.L., Nikolova V.D., Moy S.S., Sullivan P.F. Disruption of the microRNA 137 primary transcript results in early embryonic lethality in mice. Biol. Psychiatry 2015, 10.1016/j.biopsych.2014.05.022.
33. Cui Z., Feng R., Jacobs S., Duan Y., Wang H., Cao X., Tsien J.Z. Increased NR2A:NR2B ratio compresses long-term depression range and constrains long-term memory. Sci. Rep. 2013, 3:1036.
34. Cuthbert B.N., Insel T.R. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med. 2013, 11:126.
35. Dao D.T., Mahon P.B., Cai X., Kovacsics C.E., Blackwell R.A., Arad M., Shi J., Zandi P.P., O'Donnell P., Bipolar Genome Study (BiGS) Consortium, Knowles J.A., Weissman M.M., Coryell W., Scheftner W.A., Lawson W.B., Levinson D.F., Thompson S.M., Potash J.B., Gould T.D. Mood disorder susceptibility gene CACNA1C modifies mood-related behaviors in mice and interacts with sex to influence behavior in mice and diagnosis in humans. Biol. Psychiatry 2010, 68:801-810.
36. Decoster J., De Hert M., Viechtbauer W., Nagels G., Myin-Germeys I., Peuskens J., van Os J., van Winkel R. Genetic association study of the P300 endophenotype in schizophrenia. Schizophr. Res. 2012, 141:54-59.
37. -/- knockout mice. Neuropharmacology 2014, 89C:19-32.
38. Del Pino I., García-Frigola C., Dehorter N., Brotons-Mas J.R., Alvarez-Salvado E., Martínez de Lagrán M., Ciceri G., Gabaldón M.V., Moratal D., Dierssen M., Canals S., Marín O., Rico B. Erbb4 deletion from fast-spiking interneurons causes schizophrenia-like phenotypes. Neuron 2013, 79:1152-1168.
39. Desbonnet L., O'Tuathaigh C., Clarke G., O'Leary C., Petit E., Clarke N., Tighe O., Lai D., Harvey R., Cryan J.F., Dinan T.G., Waddington J.L. Phenotypic effects of repeated psychosocial stress during adolescence in mice mutant for the schizophrenia risk gene neuregulin-1: a putative model of gene×environment interaction. Brain Behav. Immun. 2012, 26:660-671.
40. Desbonnet L., Waddington J.L., Tuathaigh C.M. Mice mutant for genes associated with schizophrenia: common phenotype or distinct endophenotypes?. Behav. Brain Res. 2009, 204:258-273.
41. de Vito L.M., Balu D.T., Kanter B.R., Lykken C., Basu A.C., Coyle J.T., Eichenbaum H. Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology. Genes Brain. Behav. 2011, 10:210-222.
42. Drew M.R., Simpson E.H., Kellendonk C., Herzberg W.G., Lipatova O., Fairhurst S., Kandel E.R., Malapani C., Balsam P.D. Transient overexpression of striatal D2 receptors impairs operant motivation and interval timing. J. Neurosci. 2007, 27:7731-7739.
43. Egan M.F., Straub R.E., Goldberg T.E., Yakub I., Callicott J.H., Hariri A.R., Mattay V.S., Bertolino A., Hyde T.M., Shannon-Weickert C., Akil M., Crook J., Vakkalanka R.K., Balkissoon R., Gibbs R.A., Kleinman J.E., Weinberger D.R. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:12604-12609.
44. El-Kordi A., Winkler D., Hammerschmidt K., Kästner A., Krueger D., Ronnenberg A., Ritter C., Jatho J., Radyushkin K., Bourgeron T., Fischer J., Brose N., Ehrenreich H. Development of an autism severity score for mice using Nlgn4 null mutants as a construct-valid model of heritable monogenic autism. Behav. Brain Res. 2013, 251:41-49.
45. Ellegood J., Markx S., Lerch J.P., Steadman P.E., Genç C., Provenzano F., Kushner S.A., Henkelman R.M., Karayiorgou M., Gogos J.A. A highly specific pattern of volumetric brain changes due to 22q11.2 deletions in both mice and humans. Mol. Psychiatry 2014, 19:6.
46. Endele S., Rosenberger G., Geider K., Popp B., Tamer C., Stefanova I., Milh M., Kortüm F., Fritsch A., Pientka F.K., Hellenbroich Y., Kalscheuer V.M., Kohlhase J., Moog U., Rappold G., Rauch A., Ropers H.H., von Spiczak S., Tönnies H., Villeneuve N., Villard L., Zabel B., Zenker M., Laube B., Reis A., Wieczorek D., Van Maldergem L., Kutsche K. Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. Nat. Genet. 2010, 42:1021-1026.
47. Erk S., Meyer-Lindenberg A., Schmierer P., Mohnke S., Grimm O., Garbusow M., Haddad L., Poehland L., Mühleisen T.W., Witt S.H., Tost H., Kirsch P., Romanczuk-Seiferth N., Schott B.H., Cichon S., Nöthen M.M., Rietschel M., Heinz A., Walter H. Hippocampal and frontolimbic function as intermediate phenotype for psychosis: evidence from healthy relatives and a common risk variant in CACNA1C. Biol. Psychiatry 2014, 76:466-475.
48. Etherton M.R., Blaiss C.A., Powell C.M., Südhof T.C. Mouse neurexin-1alpha deletion causes correlated electrophysiological and behavioral changes consistent with cognitive impairments. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:17998-18003.
49. European Network of National Networks studying Gene-Environment Interactions in Schizophrenia (EU-GEI), van Os J., Rutten B.P., Myin-Germeys I., Delespaul P., Viechtbauer W., van Zelst C., Bruggeman R., Reininghaus U., Morgan C., Murray R.M., Di Forti M., McGuire P., Valmaggia L.R., Kempton M.J., Gayer-Anderson C., Hubbard K., Beards S., Stilo S.A., Onyejiaka A., Bourque F., Modinos G., Tognin S., Calem M., O'Donovan M.C., Owen M.J., Holmans P., Williams N., Craddock N., Richards A., Humphreys I., Meyer-Lindenberg A., Leweke F.M., Tost H., Akdeniz C., Rohleder C., Bumb J.M., Schwarz E., Alptekin K., Üçok A., Saka M.C., Atbaşoğlu E.C., Gülöksüz S., Gumus-Akay G., Cihan B., Karadağ H., Soygür H., Cankurtaran E.Ş., Ulusoy S., Akdede B., Binbay T., Ayer A., Noyan H., Karadayi G., Akturan E., Ulaş H., Arango C., Parellada M., Bernardo M., Sanjuán J., Bobes J., Arrojo M., Santos J.L., Cuadrado P., Rodríguez Solano J.J., Carracedo A., García Bernardo E., Roldán L., López G., Cabrera B., Cruz S., Díaz Mesa E.M., Pouso M., Jiménez E., Sánchez T., Rapado M., González E., Martínez C., Sánchez E., Olmeda M.S., de Haan L., Velthorst E., van der Gaag M., Selten J.P., van Dam D., van der Ven E., van der Meer F., Messchaert E., Kraan T., Burger N., Leboyer M., Szoke A., Schürhoff F., Llorca P.M., Jamain S., Tortelli A., Frijda F., Vilain J., Galliot A.M., Baudin G., Ferchiou A., Richard J.R., Bulzacka E., Charpeaud T., Tronche A.M., De Hert M., van Winkel R., Decoster J., Derom C., Thiery E., Stefanis N.C., Sachs G., Aschauer H., Lasser I., Winklbaur B., Schlögelhofer M., Riecher-Rössler A., Borgwardt S., Walter A., Harrisberger F., Smieskova R., Rapp C., Ittig S., Soguel-dit-Piquard F., Studerus E., Klosterkötter J., Ruhrmann S., Paruch J., Julkowski D., Hilboll D., Sham P.C., Cherny S.S., Chen E.Y., Campbell D.D., Li M., Romeo-Casabona C.M., Emaldi Cirión A., Urruela Mora A., Jones P., Kirkbride J., Cannon M., Rujescu D., Tarricone I., Berardi D., Bonora E., Seri M., Marcacci T., Chiri L., Chierzi F., Storbini V., Braca M., Minenna M.G., Donegani I., Fioritti A., La Barbera D., La Cascia C.E., Mulè A., Sideli L., Sartorio R., Ferraro L., Tripoli G., Seminerio F., Marinaro A.M., McGorry P., Nelson B., Amminger G.P., Pantelis C., Menezes P.R., Del-Ben C.M., Gallo Tenan S.H., Shuhama R., Ruggeri M., Tosato S., Lasalvia A., Bonetto C., Ira E., Nordentoft M., Krebs M.O., Barrantes-Vidal N., Cristóbal P., Kwapil T.R., Brietzke E., Bressan R.A., Gadelha A., Maric N.P., Andric S., Mihaljevic M., Mirjanic T. Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. Schizophr. Bull. 2014, 40:729-736.
50. Ey E., Yang M., Katz A.M., Woldeyohannes L., Silverman J.L., Leblond C.S., Faure P., Torquet N., Le Sourd A.M., Bourgeron T., Crawley J.N. Absence of deficits in social behaviors and ultrasonic vocalizations in later generations of mice lacking neuroligin4. Genes Brain Behav. 2012, 10.1111/j.1601-183X.2012.00849.x.
51. Fell M.J., Svensson K.A., Johnson B.G., Schoepp D.D. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J. Pharmacol. Exp. Ther. 2008, 326:209-217.
52. Feng J., Schroer R., Yan J., Song W., Yang C., Bockholt A., Cook E.H., Skinner C., Schwartz C.E., Sommer S.S. High frequency of neurexin 1beta signal peptide structural variants in patients with autism. Neurosci. Lett. 2006, 409:10-13.
53. Fitzgerald P.J., Barkus C., Feyder M., Wiedholz L.M., Chen Y.C., Karlsson R.M., Machado-Vieira R., Graybeal C., Sharp T., Zarate C., Harvey-White J., Du J., Sprengel R., Gass P., Bannerman D., Holmes A. Does gene deletion of AMPA GluA1 phenocopy features of schizoaffective disorder?. Neurobiol. Dis. 2010, 40:608-621.
54. Flint J., Munafò M.R. Genetics: finding genes for schizophrenia. Curr. Biol. 2014, 24:R755-R757.
55. Floresco S.B., Geyer M.A., Gold L.H., Grace A.A. Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia. Schizophr. Bull. 2005, 31:888-894.
56. Fromer M., Pocklington A.J., Kavanagh D.H., Williams H.J., Dwyer S., Gormley P., Georgieva L., Rees E., Palta P., Ruderfer D.M., Carrera N., Humphreys I., Johnson J.S., Roussos P., Barker D.D., Banks E., Milanova V., Grant S.G., Hannon E., Rose S.A., Chambert K., Mahajan M., Scolnick E.M., Moran J.L., Kirov G., Palotie A., McCarroll S.A., Holmans P., Sklar P., Owen M.J., Purcell S.M., O'Donovan M.C. De novo mutations in schizophrenia implicate synaptic networks. Nature 2014, 506:179-184.
57. Fujioka R., Nii T., Iwaki A., Shibata A., Ito I., Kitaichi K., Nomura M., Hattori S., Takao K., Miyakawa T., Fukumaki Y. Comprehensive behavioral study of mGluR3 knockout mice: implication in schizophrenia related endophenotypes. Mol. Brain 2014, 7:31.
58. Furnari M.A., Jobes M.L., Nekrasova T., Minden A., Wagner G.C. Differential sensitivity of Pak5, Pak6, and Pak5/Pak6 double-knockout mice to the stimulant effects of amphetamine and exercise-induced alterations in body weight. Nutr. Neurosci. 2014, 17:109-115.
59. Furnari M.A., Jobes M.L., Nekrasova T., Minden A., Wagner G.C. Functional deficits in PAK5, PAK6 and PAK5/PAK6 knockout mice. PLOS ONE 2013, 8:e61321.
60. Fusar-Poli P., Frascarelli M., Valmaggia L., Byrne M., Stahl D., Rocchetti M., Codjoe L., Weinberg L., Tognin S., Xenaki L., McGuire P. Antidepressant, antipsychotic and psychological interventions in subjects at high clinical risk for psychosis: OASIS 6-year naturalistic study. Psychol. Med. 2014, 22:1-13.
61. Gejman P.V., Sanders A.R., Kendler K.S. Genetics of schizophrenia: new findings and challenges. Annu. Rev. Genomics Hum. Genet. 2011, 12:121-144.
62. Glickstein S.B., Hof P.R., Schmauss C. Mice lacking dopamine D2 and D3 receptors have spatial working memory deficits. J. Neurosci. 2002, 22:5619-5629.
63. Glynn M.W., Elmer B.M., Garay P.A., Liu X.B., Needleman L.A., El-Sabeawy F., McAllister A.K. MHCI negatively regulates synapse density during the establishment of cortical connections. Nat. Neurosci. 2011, 14:442-451.
64. Gómez-Sintes R., Kvajo M., Gogos J.A., Lucas J.J. Mice with a naturally occurring DISC1 mutation display a broad spectrum of behaviors associated to psychiatric disorders. Front. Behav. Neurosci. 2014, 8:253.
65. Grayton H.M., Missler M., Collier D.A., Fernandes C. Altered social behaviours in neurexin 1α knockout mice resemble core symptoms in neurodevelopmental disorders. PLOS ONE 2013, 8:e67114.
66. Green M.J., Cairns M.J., Wu J., Dragovic M., Jablensky A., Tooney P.A., Scott R.J., Carr V.J., Australian Schizophrenia Research Bank Genome-wide supported variant MIR137 and severe negative symptoms predict membership of an impaired cognitive subtype of schizophrenia. Mol. Psychiatry 2012, 18:774-780.
67. Gregor A., Albrecht B., Bader I., Bijlsma E.K., Ekici A.B., Engels H., Hackmann K., Horn D., Hoyer J., Klapecki J., Kohlhase J., Maystadt I., Nagl S., Prott E., Tinschert S., Ullmann R., Wohlleber E., Woods G., Reis A., Rauch A., Zweier C. Expanding the clinical spectrum associated with defects in CNTNAP2 and NRXN1. BMC Med. Genet. 2011, 12:106.
68. Hagiwara H., Iyo M., Hashimoto K. Neonatal disruption of serine racemase causes schizophrenia-like behavioral abnormalities in adulthood: clinical rescue by d-serine. PLOS ONE 2013, 8:e62438.
69. Hall J., Trent S., Thomas K.L., O'Donovan M.C., Owen M.J. Genetic risk for schizophrenia: convergence on synaptic pathways involved in plasticity. Biol. Psychiatry 2014, pii: S0006-3223(14)00519-8.
70. Hamshere M.L., Walters J.T., Smith R., Richards A.L., Green E., Grozeva D., Jones I., Forty L., Jones L., Gordon-Smith K., Riley B., O'Neill F.A., Kendler K.S., Sklar P., Purcell S., Kranz J., Schizophrenia Psychiatric Genome-wide Association Study Consortium, Wellcome Trust Case Control Consortium+, Wellcome Trust Case Control Consortium 2, Morris D., Gill M., Holmans P., Craddock N., Corvin A., Owen M.J., O'Donovan M.C. Genome-wide significant associations in schizophrenia to ITIH3/4, CACNA1C and SDCCAG8, and extensive replication of associations reported by the Schizophrenia PGC. Mol. Psychiatry 2013, 18:708-712.
71. Harrison P.J., Pritchett D., Stumpenhorst K., Betts J.F., Nissen W., Schweimer J., Lane T., Burnet P.W., Lamsa K.P., Sharp T., Bannerman D.M., Tunbridge E.M. Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia. Neuropharmacology 2012, 62:1164-1167.
72. Hashimoto A., Yoshikawa M., Niwa A., Konno R. Mice lacking d-amino acid oxidase activity display marked attenuation of stereotypy and ataxia induced by MK-801. Brain Res. 2005, 1033:210-215.
73. Hayashi-Takagi A., Araki Y., Nakamura M., Vollrath B., Duron S.G., Yan Z., Kasai H., Huganir R.L., Campbell D.A., Sawa A. PAKs inhibitors ameliorate schizophrenia-associated dendritic spine deterioration in vitro and in vivo during late adolescence. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:6461-6466.
74. Hemani G., Knott S., Haley C. An evolutionary perspective on epistasis and the missing heritability. PLoS Genet. 2013, 9:e1003295.
75. Hennah W., Thomson P., McQuillin A., Bass N., Loukola A., Anjorin A., Blackwood D., Curtis D., Deary I.J., Harris S.E., Isometsa E.T., Lawrence J., Lonnqvist J., Muir W., Palotie A., Partonen T., Paunio T., Pylkko E., Robinson M., Soronen P., Suominen K., Suvisaari J., Thirumalai S., St Clair D., Gurling H., Peltonen L., Porteous D. DISC1 association, heterogeneity and interplay in schizophrenia and bipolar disorder. Mol. Psychiatry 2009, 14:865-873.
76. Hikida T., Jaaro-Peled H., Seshadri S., Oishi K., Hookway C., Kong S., Wu D., Xue R., Andrade M., Tankou S., Mori S., Gallagher M., Ishizuka K., Pletnikov M., Kida S., Sawa A. Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:14501-14506.
77. Hikida T., Gamo N.J., Sawa A. DISC1 as a therapeutic target for mental illnesses. Expert Opin. Ther. Targets 2012, 16:1151-1160.
78. Hodgkinson C.A., Goldman D., Jaeger J., Persaud S., Kane J.M., Lipsky R.H., Malhotra A.K. Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am. J. Hum. Genet. 2004, 75:862-875.
79. Howes O.D., Murray R.M. Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet 2014, 383:1677-1687.
80. Huang K.P., Huang F.L., Jäger T., Li J., Reymann K.G., Balschun D. Neurogranin/RC3 enhances long-term potentiation and learning by promoting calcium-mediated signaling. J. Neurosci. 2004, 24:10660-10669.
81. Huang F.L., Huang K.P., Boucheron C. Long-term enrichment enhances the cognitive behavior of the aging neurogranin null mice without affecting their hippocampal LTP. Learn. Mem. 2007, 14:512-519.
82. Huang F.L., Huang K.P. Methylphenidate improves the behavioral and cognitive deficits of neurogranin knockout mice. Genes Brain Behav. 2012, 11:794-805.
83. Huh G.S., Boulanger L.M., Du H., Riquelme P.A., Brotz T.M., Shatz C.J. Functional requirement for class I MHC in CNS development and plasticity. Science 2000, 290:2155-2159.
84. Humby T., Wilkinson L.S. Assaying dissociable elements of behavioural inhibition and impulsivity: translational utility of animal models. Curr. Opin. Pharmacol. 2011, 11:534-539.
85. Hyman S.E. Time for new schizophrenia Rx. Science 2014, 343:1177.
86. Ibi D., Nagai T., Kitahara Y., Mizoguchi H., Koike H., Shiraki A., et al. Neonatal polyI:C treatment in mice results in schizophrenia-like behavioral and neurochemical abnormalities in adulthood. Neurosci. Res. 2009, 64:297-305.
87. Ichtchenko K., Hata Y., Nguyen T., et al. Neuroligin 1: a splice site-specific ligand for beta-neurexins. Cell 1995, 81:435-443.
88. Ikeda M., Aleksic B., Kirov G., Kinoshita Y., Yamanouchi Y., Kitajima T., Kawashima K., Okochi T., Kishi T., Zaharieva I., Owen M.J., O'Donovan M.C., Ozaki N., Iwata N. Copy number variation in schizophrenia in the Japanese population. Biol. Psychiatry 2010, 67:283-286.
89. Insel T. Rethinking schizophrenia. Nature 2010, 468:187-193.
90. Inta D., Vogt M.A., Elkin H., Weber T., Lima-Ojeda J.M., Schneider M., Luoni A., Riva M.A., Gertz K., Hellmann-Regen J., Kronenberg G., Meyer-Lindenberg A., Sprengel R., Gass P. Phenotype of mice with inducible ablation of GluA1 AMPA receptors during late adolescence: relevance for mental disorders. Hippocampus 2014, 24:424-435.
91. International Schizophrenia Consortium Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 2008, 455:237-241.
92. International Schizophrenia Consortium, Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., Sullivan P.F., Sklar P. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460(7256):748-752.
93. Jamain S., Radyushkin K., Hammerschmidt K., Granon S., Boretius S., Varoqueaux F., Ramanantsoa N., Gallego J., Ronnenberg A., Winter D., Frahm J., Fischer J., Bourgeron T., Ehrenreich H., Brose N. Reduced social interaction and ultrasonic communication in a mouse model of monogenic heritable autism. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:1710-1715.
94. Jia J.M., Zhao J., Hu Z.H., Lindberg D., Li Z. Age-dependent regulation of synaptic connections by dopamine D2 receptors. Nat. Neurosci. 2013, 16:1627-1636.
95. Jonas R.K., Montojo C.A., Bearden C.E. The 22q11.2 deletion syndrome as a window into complex neuropsychiatric disorders over the lifespan. Biol. Psychiatry 2014, 75:351-360.
96. Ju A., Hammerschmidt K., Tantra M., Krueger D., Brose N., Ehrenreich H. Juvenile manifestation of ultrasound communication deficits in the neuroligin-4 null mutant mouse model of autism. Behav. Brain Res. 2014, 270:159-164.
97. Kannan G., Sawa A., Pletnikov M.V. Mouse models of gene-environment interactions in schizophrenia. Neurobiol. Dis. 2013, 57:5-11.
98. Karayiorgou M., Simon T.J., Gogos J.A. 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. Nat. Rev. Neurosci. 2010, 11:402-416.
99. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J. Psychiatry 2003, 160:13-23.
100. Kapur S., Phillips A.G., Insel T.R. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it?. Mol. Psychiatry 2012, 17:1174-1179.
101. Karam C.S., Ballon J.S., Bivens N.M., Freyber Z., Girgis R.R., Lizardi-Ortiz J.E., Markx S., Lieberman J.A., Javitch J.A. Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends Pharmacol. Sci. 2010, 31:381-390.
102. Katsnelson A. Drug development: the modelling challenge. Nature 2014, 508:S8-S9.
103. Kawakubo Y., Suga M., Tochigi M., Yumoto M., Itoh K., Sasaki T., Kano Y., Kasai K. Effects of metabotropic glutamate receptor 3 genotype on phonetic mismatch negativity. PLoS ONE 2011, 6:e24929.
104. Kellendonk C., Simpson E.H., Polan H.J., Malleret G., Vronskaya S., Winiger V., Moore H., Kandel E.R. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 2006, 49:603-615.
105. Kilpinen H., Ylisaukko-Oia T., Hennah W., Palo O.M., Varilo T., Vanhala R., Nieminen-von Wendt T., von Wendt L., Paunio T., Peltonen L. Association of DISC1 with autism and Asperger syndrome. Mol. Psychiatry 2008, 13:187-196.
106. Kinon B.J., Zhang L., Millen B.A., Osuntokun O.O., Williams J.E., Kollack-Walker S., Jackson K., Kryzhanovskaya L., Jarkova N., HBBI Study Group A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J. Clin. Psychopharmacol. 2011, 31:349-355.
107. Kirby B.P., Waddington J.L., O'Tuathaigh C.M. Advancing a functional genomics for schizophrenia: psychopathological and cognitive phenotypes in mutants with gene disruption. Brain Res. Bull. 2010, 83:162-176.
108. Kirov G., Gumus D., Chen W., Norton N., Georgieva L., Sari M., O'Donovan M.C., Erdogan F., Owen M.J., Ropers H.H., Ullmann R. Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. Hum. Mol. Genet. 2008, 17:458-465.
109. Kirov G., Rujescu D., Ingason A., Collier D.A., O'Donovan M.C., Owen M.J. Neurexin 1 (NRXN1) deletions in schizophrenia. Schizophr. Bull. 2009, 35:851-854.
110. Kirov G., Pocklington A.J., Holmans P., Ivanov D., Ikeda M., Ruderfer D., Moran J., Chambert K., Toncheva D., Georgieva L., Grozeva D., Fjodorova M., Wollerton R., Rees E., Nikolov I., van de Lagemaat L.N., Bayés A., Fernandez E., Olason P.I., Böttcher Y., Komiyama N.H., Collins M.O., Choudhary J., Stefansson K., Stefansson H., Grant S.G., Purcell S., Sklar P., O'Donovan M.C., Owen M.J. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol. Psychiatry 2012, 17:142-153.
111. Koike H., Arguello P.A., Kvajo M., Karayiorgou M., Gogos J.A. Disc1 is mutated in the 129S6/SvEv strain and modulates working memory in mice. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:3693-3697.
112. Kopec C.D., Real E., Kessels H.W., Malinow R. GluR1 links structural and functional plasticity at excitatory synapses. J. Neurosci. 2007, 27:13706-13718.
113. Kuepper R., Skinbjerg M., Abi-Dargham A. The dopamine dysfunction in schizophrenia revisited: new insights into topography and course. Handb. Exp. Pharmacol. 2012, 212:1-26.
114. Kuroda K., Yamada S., Tanaka M., Iizuka M., Yano H., Mori D., Tsuboi D., Nishioka T., Namba T., Iizuka Y., Kubota S., Nagai T., Ibi D., Wang R., Enomoto A., Isotani-Sakakibara M., Asai N., Kimura K., Kiyonari H., Abe T., Mizoguchi A., Sokabe M., Takahashi M., Yamada K., Kaibuchi K. Behavioral alterations associated with targeted disruption of exons 2 and 3 of the Disc1 gene in the mouse. Hum. Mol. Genet. 2011, 20:4666-4683.
115. Kvajo M., McKellar H., Arguello P.A., Drew L.J., Moore H., MacDermott A.B., Karayiorgou M., Gogos J.A. A mutation in mouse Disc 1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:7076-7081.
116. Labrie V., Lipina T., Roder J.C. Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. Psychopharmacology (Berl.) 2008, 200:217-230.
117. Lainiola M., Procaccini C., Linden A.M. mGluR3 knockout mice show a working memory defect and an enhanced response to MK-801 in the T- and Y-maze cognitive tests. Behav. Brain Res. 2014, 266:94-103.
118. Lane T.A., Boerner T., Bannerman D.M., Kew J.N., Tunbridge E.M., Sharp T., Harrison P.J. Decreased striatal dopamine in group II metabotropic glutamate receptor (mGlu2/mGlu3) double knockout mice. BMC Neurosci. 2013, 14:102.
119. Lee A.S., Ra S., Rajadhyaksha A.M., Britt J.K., De Jesus-Cortes H., Gonzales K.L., Lee A., Moosmang S., Hofmann F., Pieper A.A., Rajadhyaksha A.M. Forebrain elimination of cacna1c mediates anxiety-like behavior in mice. Mol. Psychiatry 2012, 17:1054-1055.
120. Lee A.S., Gonzales K.L., Lee A., Moosmang S., Hofmann F., Pieper A.A., Rajadhyaksha A.M. Selective genetic deletion of cacna1c in the mouse prefrontal cortex. Mol. Psychiatry 2012, 17:1051.
121. Lee K.W., Woon P.S., Teo Y.Y., Sim K. Genome wide association studies (GWAS) and copy number variation (CNV) studies of the major psychoses: what have we learnt?. Neurosci. Biobehav. Rev. 2012, 36:556-571.
122. Lehner B. Molecular mechanisms of epistatis within and between genes. Trends Genet. 2011, 27:323-331.
123. Levinson D.F., Duan J., Oh S., Wang K., Sanders A.R., Shi J., Zhang N., Mowry B.J., Olincy A., Amin F., Cloninger C.R., Silverman J.M., Buccola N.G., Byerley W.F., Black D.W., Kendler K.S., Freedman R., Dudbridge F., Pe'er I., Hakonarson H., Bergen S.E., Fanous A.H., Holmans P.A., Gejman P.V. Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. Am. J. Psychiatry 2011, 168:302-316.
124. Li W., Zhou Y., Jentsch J.D., Brown R.A.M., Tian X., Ehninger D. Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:18280-18285.
125. Lipina T.V., Kaidanovich-Beilin O., Patel S., Wang M., Clapcote S.J., Liu F., Woodgett J.R., Roder J.C. Genetic and pharmacological evidence for schizophrenia-related Disc1 interaction with GSK-3. Synapse 2011, 65:234-248.
126. Low N.C., Hardy J. What is a schizophrenic mouse?. Neuron 2007, 54:348-349.
127. Ma T.M., Abazyan S., Abazyan B., Nomura J., Yang C., Seshadri S., Sawa A., Snyder S.H., Pletnikov M.V. Pathogenic disruption of DISC1-serine racemase binding elicits schizophrenia-like behavior via d-serine depletion. Mol. Psychiatry 2013, 18:557-567.
128. Maksimovic M., Vekovischeva O.Y., Aitta-aho T., Korpi E.R. Chronic treatment with mood-stabilizers attenuates abnormal hyperlocomotion of GluA1-subunit deficient mice. PLOS ONE 2014, 9:e100188.
129. Mao Y., Ge X., Frank C.L., Madison J.M., Koehler A.N., Doud M.K., Tassa C., Berry E.M., Soda T., Singh K.K., Biechele T., Petryshen T.L., Moon R.T., Haggarty S.J., Tsai L.H. Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signalling. Cell 2009, 136:1017-1031.
130. Marenco S., Steele S.U., Egan M.F., Goldberg T.E., Straub R.E., Sharrief A.Z., Weinberger D.R. Effect of metabotropic glutamate receptor 3 genotype on N-acetylaspartate measures in the dorsolateral prefrontal cortex. Am. J. Psychiatry 2006, 163:740-742.
131. McCarroll S.A., Feng G., Hyman S.E. Genome-scale neurogenetics: methodology and meaning. Nat. Neurosci. 2014, 17:756-763.
132. Mead A.N., Stephens D.N. Selective disruption of stimulus-reward learning in glutamate receptor gria1 knock-out mice. J. Neurosci. 2003, 23:1041-1048.
133. Mead A.N., Brown G., Le Merrer J., Stephens D.N. Effects of deletion of gria1 or gria2 genes encoding glutamatergic AMPA-receptor subunits on place preference conditioning in mice. Psychopharmacology (Berl.) 2005, 179:164-171.
134. Meck M.H., Cheng R.K., MacDonald C.J., Gainetdinov R.R., Caron M.G., Cevik M.O. Gene-dose dependent effects of methamphetamine on interval timing in dopamine-transporter mice. Neuropharmacology 2012, 62:1221-1229.
135. Meyer-Lindenberg A., Tost H. Neural mechanisms of social risk for psychiatric disorders. Nat. Neurosci. 2012, 15:663-668.
136. Millar J.K., Wilson-Annan J.C., Anderson S., Christie S., Taylor M.S., Semple C.A., Devon R.S., St Clair D.M., Muir W.J., Blackwood D.H., Porteous D.J. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum. Mol. Genet. 2000, 9:1415-1423.
137. Millar J.K., Pickard B.S., Mackie S., James R., Christie S., Buchanan S.R., Malloy M.P., Chubb J.E., Huston E., Baillie G.S., Thomson P.A., Hill E.V., Brandon N.J., Rain J.C., Camargo L.M., Whiting P.J., Houslay M.D., Blackwood D.H., Muir W.J., Porteous D.J. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signalling. Science 2005, 310:1187-1191.
138. Miyakawa T., Yared E., Pak J.H., Huang F.L., Huang K.P., Crawley J.N. Neurogranin null mutant mice display performance deficits on spatial learning tasks with anxiety related components. Hippocampus 2001, 11:763-775.
139. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998, 281:1349-1352.
140. Moore T.H., Zammit S., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370:319-328.
141. Moran P.M., O'Tuathaigh C.M., Papaleo F., Waddington J.L. Dopaminergic function in relation to genes associated with risk for schizophrenia: translational mutant mouse models. Prog. Brain Res. 2014, 211:79-112.
142. Moser P.C., Hitchcock J.M., Lister S., Moran P.M. The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Res. Rev. 2000, 33:275-307.
143. Moy S.S., Nadler J.J., Perez A., Barbaro R.P., Johns J.M., Magnuson T.R., Piven J., Crawley J.N. Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice. Genes Brain. Behav. 2004, 3:287-302.
144. Muglia P. From genes to therapeutic targets for psychiatric disorders - what to expect?. Curr. Opin. Pharmacol. 2011, 11:563-571.
145. Nakai T., Nagai T., Wang R., Yamada S., Kuroda K., Kaibuchi K., Yamada K. Alterations of GABAergic and dopaminergic systems in mutant mice with disruption of exons 2 and 3 of the Disc1 gene. Neurochem. Int. 2014, 74:74-83.
146. Nekrasova T., Jobes M.L., Ting J.H., Wagner G.C., Minden A. Targeted disruption of the Pak5 and Pak6 genes in mice leads to deficits in learning and locomotion. Dev. Biol. 2008, 322:95-108.
147. Nicodemus K.K., Law A.J., Radulescu E., Luna A., Kolachana B., Vakkalanka R., Rujescu D., Giegling I., Straub R.E., McGee K., Gold B., Dean M., Muglia P., Callicott J.H., Tan H.Y., Weinberger D.R. Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls. Arch. Gen. Psychiatry 2010, 67:991-1001.
148. Nicodemus K.K., Hargreaves A., Morris D., Anney R., Gill M., Corvin A., Donohoe G., Schizophrenia Psychiatric Genome-wide Association Study (GWAS) Consortium, Wellcome Trust Case Control Consortium 2 Variability in working memory performance explained by epistasis vs polygenic scores in the ZNF804A pathway. JAMA Psychiatry 2014, 71:778-785.
149. Nolan M.F., Malleret G., Dudman J.T., Buhl D.L., Santoro B., Gibbs E., Vronskaya S., Buzsáki G., Siegelbaum S.A., Kandel E.R., Morozov A. A behavioral role for dendritic integration: HCN1 channels constrain spatial memory and plasticity at inputs to distal dendrites of CA1 pyramidal neurons. Cell 2004, 119:719-732.
150. Oliver P.L., Davies K.E. Interaction between environmental and genetic factors modulates schizophrenic endophenotypes in the Snap-25 mouse mutant blind-drunk. Hum. Mol. Genet. 2009, 18:4576-4589.
151. O'Leary C., Desbonnet L., Clarke N., Petit E., Tighe O., Lai D., Harvey R., Waddington J.L., O'Tuathaigh C. Phenotypic effects of maternal immune activation and early postnatal milieu in mice mutant for the schizophrenia risk gene neuregulin-1. Neuroscience 2014, 277:294-305.
152. O'Tuathaigh C.M., Hryniewiecka M., Behan A., Tighe O., Coughlan C., Desbonnet L., Cannon M., Karayiorgou M., Gogos J.A., Cotter D.R., Waddington J.L. Chronic adolescent exposure to delta-9-tetrahydrocannabinol in COMT mutant mice: impact on psychosis-related and other phenotypes. Neuropsychopharmacology 2010, 35:2262-2273.
153. O'Tuathaigh C.M., Clarke G., Walsh J., Desbonnet L., Petit E., O'Leary C., Tighe O., Clarke N., Karayiorgou M., Gogos J.A., Dinan T.G., Cryan J.F., Waddington J.L. Genetic vs. pharmacological inactivation of COMT influences cannabinoid-induced expression of schizophrenia-related phenotypes. Int. J. Neuropsychopharmacol. 2012, 15:1331-1342.
154. O'Tuathaigh C.M., Desbonnet L., Waddington J.L. Genetically modified mice related to schizophrenia and other psychoses: seeking phenotypic insights into the pathobiology and treatment of negative symptoms. Eur. Neuropsychopharmacol. 2014, 24:800-821.
155. Owen M.J. Implications of genetic findings for understanding schizophrenia. Schizophr. Bull. 2012, 38:904-907.
156. Owoeye O., Kingston T., Scully P.J., Baldwin P., Browne D., Kinsella A., Russell V., O'Callaghan E., Waddington J.L. Epidemiological and clinical characterization following a first psychotic episode in major depressive disorder: comparisons with schizophrenia and bipolar I disorder in the Cavan-Monaghan First Episode Psychosis Study (CAMFEPS). Schizophr. Bull. 2013, 39:756-765.
157. Paciorkowski A.R., Traylor R.N., Rosenfeld J.A., Hoover J.M., Harris C.J., Winter S., Lacassie Y., Bialer M., Lamb A.N., Schultz R.A., Berry-Kravis E., Porter B.E., Falk M., Venkat A., Vanzo R.J., Cohen J.S., Fatemi A., Dobyns W.B., Shaffer L.G., Ballif B.C., Marsh E.D. MEF2C haploinsufficiency features consistent hyperkinesis, variable epilepsy, and has a role in dorsal and ventral neuronal developmental pathways. Neurogenetics 2013, 14:99-111.
158. Pak J.H., Huang F.L., Li J., Balschun D., Reymann K.G., Chiang C., Westphal H., Huang K.P. Involvement of neurogranin in the modulation of calcium/calmodulin-dependent protein kinase II, synaptic plasticity, and spatial learning: a study with knockout mice. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:11232-11237.
159. Papaleo F., Lipska B.K., Weinberger D.R. Mouse models of genetic effects on cognition: relevance to schizophrenia. Neuropharmacology 2011, 62:1204-1220.
160. Papaleo F., Burdick M.C., Callicott J.H., Weinberger D.R. Epistatic interaction between COMT and DTNBP1 modulates prefrontal function in mice and in humans. Mol. Psychiatry 2014, 19:311-316.
161. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., Mosolov S.N., Neznanov N.G., Reznik A.M., Smulevich A.B., Tochilov V.A., Johnson B.G., Monn J.A., Schoepp D.D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 2007, 13:1102-1107.
162. Pletnikov M.V., Ayhan Y., Nikolskaia O., Xu Y., Ovanesov M.V., Huang H. Inducible expression of mutant human DISC1 in mice is associated with brain and behavioural abnormalities reminiscent of schizophrenia. Mol. Psychiatry 2008, 13:173-186.
163. Porteous D.J., Thomson P.A., Millar J.K., Evans K.L., Hennah W., Soares D.C., McCarthy S., McCombie W.R., Clapcote S.J., Korth C., Brandon N.J., Sawa A., Kamiya A., Roder J.C., Lawrie S.M., McIntosh A.M., St Clair D., Blackwood D.H. DISC1 as a genetic risk factor for schizophrenia and related major mental illness: response to Sullivan. Mol. Psychiatry 2014, 19:141-143.
164. Prasad S.E., Katina S., Hennesy R.J., Murphy K.C., Bowman A., Waddington J.L. Craniofacial dysmorphology in 22q11.2 deletion syndrome by 3D laser surface imaging and geometric morphometrics: illuminating the developmental relationship to risk for psychosis. Am. J. Med. Genet. 2015, (in press).
165. Procaccini C., Aitta-aho T., Jaako-Movits K., Zharkovsky A., Panhelainen A., Sprengel R., Linden A.M., Korpi E.R. Excessive novelty-induced c-Fos expression and altered neurogenesis in the hippocampus of GluA1 knockout mice. Eur. J. Neurosci. 2011, 33:161-174.
166. Procaccini C., Maksimovic M., Aitta-Aho T., Korpi E.R., Linden A.M. Reversal of novelty-induced hyperlocomotion and hippocampal c-Fos expression in GluA1 knockout male mice by the mGluR2/3 agonist LY354740. Neuroscience 2013, 250:189-200.
167. Purcell S.M., Moran J.L., Fromer M., Ruderfer D., Solovieff N., Roussos P., O'Dushlaine C., Chambert K., Bergen S.E., Kähler A., Duncan L., Stahl E., Genovese G., Fernández E., Collins M.O., Komiyama N.H., Choudhary J.S., Magnusson P.K., Banks E., Shakir K., Garimella K., Fennell T., DePristo M., Grant S.G., Haggarty S.J., Gabriel S., Scolnick E.M., Lander E.S., Hultman C.M., Sullivan P.F., McCarroll S.A., Sklar P. A polygenic burden of rare disruptive mutations in schizophrenia. Nature 2015, 506:185-190.
168. Rapoport J.L., Giedd J.N., Gogtay N. Neurodevelopmental model of schizophrenia: update 2012. Mol. Psychiatry 2012, 17:1228-1238.
169. Resnik E., McFarland J.M., Sprengel R., Sakmann B., Mehta M.R. The effects of GluA1 deletion on the hippocampal population code for position. J. Neurosci. 2012, 32:8952-8968.
170. Reutlinger C., Helbig I., Gawelczyk B., Subero J.I., Tönnies H., Muhle H., Finsterwalder K., Vermeer S., Pfundt R., Sperner J., Stefanova I., Gillessen-Kaesbach G., von Spiczak S., van Baalen A., Boor R., Siebert R., Stephani U., Caliebe A. Deletions in 16p13 including GRIN2A in patients with intellectual disability, various dysmorphic features, and seizure disorders of the rolandic region. Epilepsia 2010, 51:1870-1873.
171. Ripke S., O'Dushlaine C., Chambert K., Moran J.L., Kähler A.K., Akterin S., Bergen S.E., Collins A.L., Crowley J.J., Fromer M., Kim Y., Lee S.H., Magnusson P.K., Sanchez N., Stahl E.A., Williams S., Wray N.R., Xia K., Bettella F., Borglum A.D., Bulik-Sullivan B.K., Cormican P., Craddock N., de Leeuw C., Durmishi N., Gill M., Golimbet V., Hamshere M.L., Holmans P., Hougaard D.M., Kendler K.S., Lin K., Morris D.W., Mors O., Mortensen P.B., Neale B.M., O'Neill F.A., Owen M.J., Milovancevic M.P., Posthuma D., Powell J., Richards A.L., Riley B.P., Ruderfer D., Rujescu D., Sigurdsson E., Silagadze T., Smit A.B., Stefansson H., Steinberg S., Suvisaari J., Tosato S., Verhage M., Walters J.T., Multicenter Genetic Studies of Schizophrenia Consortium, Levinson D.F., Gejman P.V., Kendler K.S., Laurent C., Mowry B.J., O'Donovan M.C., Owen M.J., Pulver A.E., Riley B.P., Schwab S.G., Wildenauer D.B., Dudbridge F., Holmans P., Shi J., Albus M., Alexander M., Campion D., Cohen D., Dikeos D., Duan J., Eichhammer P., Godard S., Hansen M., Lerer F.B., Liang K.Y., Maier W., Mallet J., Nertney D.A., Nestadt G., Norton N., O'Neill F.A., Papadimitriou G.N., Ribble R., Sanders A.R., Silverman J.M., Walsh D., Williams N.M., Wormley B., Psychosis Endophenotypes International Consortium, Arranz M.J., Bakker S., Bender S., Bramon E., Collier D., Crespo-Facorro B., Hall J., Iyegbe C., Jablensky A., Kahn R.S., Kalaydjieva L., Lawrie S., Lewis C.M., Lin K., Linszen D.H., Mata I., McIntosh A., Murray R.M., Ophoff R.A., Powell J., Rujescu D., Van Os J., Walshe M., Weisbrod M., Wiersma D., Wellcome Trust Case Control Consortium 2, Donnelly P., Barroso I., Blackwell J.M., Bramon E., Brown M.A., Casas J.P., Corvin A.P., Deloukas P., Duncanson A., Jankowski J., Markus H.S., Mathew C.G., Palmer C.N., Plomin R., Rautanen A., Sawcer S.J., Trembath R.C., Viswanathan A.C., Wood N.W., Spencer C.C., Band G., Bellenguez C., Freeman C., Hellenthal G., Giannoulatou E., Pirinen M., Pearson R.D., Strange A., Su Z., Vukcevic D., Donnelly P., Langford C., Hunt S.E., Edkins S., Gwilliam R., Blackburn H., Bumpstead S.J., Dronov S., Gillman M., Gray E., Hammond N., Jayakumar A., McCann O.T., Liddle J., Potter S.C., Ravindrarajah R., Ricketts M., Tashakkori-Ghanbaria A., Waller M.J., Weston P., Widaa S., Whittaker P., Barroso I., Deloukas P., Mathew C.G., Blackwell J.M., Brown M.A., Corvin A.P., McCarthy M.I., Spencer C.C., Bramon E., Corvin A.P., O'Donovan M.C., Stefansson K., Scolnick E., Purcell S., McCarroll S.A., Sklar P., Hultman C.M., Sullivan P.F. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat. Genet. 2013, 45:1150-1159.
172. Rose E.J., Morris D.W., Fahey C., Robertson I.H., Greene C., O'Doherty J., Newell F.N., Garavan H., McGrath J., Bokde A., Tropea D., Gill M., Corvin A.P., Donohoe G. The effect of the neurogranin schizophrenia risk variant rs12807809 on brain structure and function. Twin Res. Hum. Genet. 2012, 15:296-303.
173. Rudd D.S., Axelsen M., Epping E.A., Andreasen N.C., Wassink T.H. A genome-wide CNV analysis of schizophrenia reveals a potential role for a multiple-hit model. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2014, 10.1002/ajmg.b.32266.
174. Ruderfer D.M., Fanous A.H., Ripke S., McQuillin A., Amdur R.L., Schizophrenia Working Group of Psychiatric Genomics Consortium, Bipolar Disorder Working Group of Psychiatric Genomics Consortium, Cross-Disorder Working Group of Psychiatric Genomics Consortium, Gejman P.V., O'Donovan M.C., Andreassen O.A., Djurovic S., Hultman C.M., Kelsoe J.R., Jamain S., Landén M., Leboyer M., Nimgaonkar V., Nurnberger J., Smoller J.W., Craddock N., Corvin A., Sullivan P.F., Holmans P., Sklar P., Kendler K.S. Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia. Mol. Psychiatry 2014, 19:1017-1024.
175. Rujescu D., Ingason A., Cichon S., Pietiläinen O.P., Barnes M.R., Toulopoulou T., Picchioni M., Vassos E., Ettinger U., Bramon E., Murray R., Ruggeri M., Tosato S., Bonetto C., Steinberg S., Sigurdsson E., Sigmundsson T., Petursson H., Gylfason A., Olason P.I., Hardarsson G., Jonsdottir G.A., Gustafsson O., Fossdal R., Giegling I., Möller H.J., Hartmann A.M., Hoffmann P., Crombie C., Fraser G., Walker N., Lonnqvist J., Suvisaari J., Tuulio-Henriksson A., Djurovic S., Melle I., Andreassen O.A., Hansen T., Werge T., Kiemeney L.A., Franke B., Veltman J., Buizer-Voskamp J.E., GROUP Investigators, Sabatti C., Ophoff R.A., Rietschel M., Nöthen M.M., Stefansson K., Peltonen L., St Clair D., Stefansson H., Collier D.A. Disruption of the neurexin 1 gene is associated with schizophrenia. Hum. Mol. Genet. 2009, 18:988-996.
176. Sanderson D.J., Gray A., Simon A., Taylor A.M., Deacon R.M., Seeburg P.H., Sprengel R., Good M.A., Rawlins J.N., Bannerman D.M. Deletion of glutamate receptor-A (GluR-A) AMPA receptor subunits impairs one-trial spatial memory. Behav. Neurosci. 2007, 121:559-569.
177. Sanderson D.J., Good M.A., Skelton K., Sprengel R., Seeburg P.H., Rawlins J.N., Bannerman D.M. Enhanced long-term and impaired short-term spatial memory in GluA1 AMPA receptor subunit knockout mice: evidence for a dual-process memory model. Learn. Mem. 2009, 16:379-386.
178. Sanderson D.J., McHugh S.B., Good M.A., Sprengel R., Seeburg P.H., Rawlins J.N., Bannerman D.M. Spatial working memory deficits in GluA1 AMPA receptor subunit knockout mice reflect impaired short-term habituation: evidence for Wagner's dual-process memory model. Neuropsychologia 2010, 48:2303-2315.
179. Sanderson D.J., Hindley E., Smeaton E., Denny N., Taylor A., Barkus C., Sprengel R., Seeburg P.H., Bannerman D.M. Deletion of the GluA1 AMPA receptor subunit impairs recency-dependent object recognition memory. Learn. Mem. 2011, 18:181-190.
180. Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 2011, 43:969-976.
181. Schizophrenia Working Group of the Psychiatric Genomics Consortium Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014, 511:421-427.
182. Schmitt W.B., Deacon R.M., Seeburg P.H., Rawlins J.N., Bannerman D.M. A within-subjects, within-task demonstration of intact spatial reference memory and impaired spatial working memory in glutamate receptor-A-deficient mice. J. Neurosci. 2003, 23:3953-3959.
183. Shatz C.J. MHC class I: an unexpected role in neuronal plasticity. Neuron 2009, 64:40-45.
184. Shen S., Lang B., Nakamoto C., Zhang F., Pu J., Kuan S.L., Chatzi C., He S., Mackie I., Brandon N.J., Marquis K.L., Day M., Hurko O., McCaig C.D., Riedel G., St Clair D. Schizophrenia-related neural and behavioural phenotypes in transgenic mice expressing truncated DISC1. J. Neurosci. 2008, 28:10893-10904.
185. Shi J., Levinson D.F., Duan J., Sanders A.R., Zheng Y., Pe'er I., Dudbridge F., Holmans P.A., Whittemore A.S., Mowry B.J., Olincy A., Amin F., Cloninger C.R., Silverman J.M., Buccola N.G., Byerley W.F., Black D.W., Crowe R.R., Oksenberg J.R., Mirel D.B., Kendler K.S., Freedman R., Gejman P.V. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009, 460:753-757.
186. Shoji H., Toyama K., Takamiya Y., Wakana S., Gondo Y., Miyakawa T. Comprehensive behavioral analysis of ENU-induced Disc1-Q31L and -L100P mutant mice. BMC Res. Notes 2012, 5:108.
187. Sigurdsson T., Stark K.L., Karayiorgou M., Gogos J.A., Gordon J.A. Impaired hippocampal-prefrontal synchrony in a genetic mouse model of schizophrenia. Nature 2010, 464:763-767.
188. Simpson E.H., Kellendonk C., Ward R.D., Richards V., Lipatova O., Fairhurst S., Kandel E.R., Balsam P.D. Pharmacologic rescue of motivational deficit in an animal model of the negative symptoms of schizophrenia. Biol. Psychiatry 2011, 69:928-935.
189. Sklar P., Smoller J.W., Fan J., Ferreira M.A., Perlis R.H., Chambert K., Nimgaonkar V.L., McQueen M.B., Faraone S.V., Kirby A., de Bakker P.I., Ogdie M.N., Thase M.E., Sachs G.S., Todd-Brown K., Gabriel S.B., Sougnez C., Gates C., Blumenstiel B., Defelice M., Ardlie K.G., Franklin J., Muir W.J., McGhee K.A., MacIntyre D.J., McLean A., VanBeck M., McQuillin A., Bass N.J., Robinson M., Lawrence J., Anjorin A., Curtis D., Scolnick E.M., Daly M.J., Blackwood D.H., Gurling H.M., Purcell S.M. Whole-genome association study of bipolar disorder. Mol. Psychiatry 2008, 13:558-569.
190. Smrt R.D., Szulwach K.E., Pfeiffer R.L., Li X., Guo W., Pathania M., Teng Z.Q., Luo Y., Peng J., Bordey A., Jin P., Zhao X. MicroRNA miR-137 regulates neuronal maturation by targeting ubiquitin ligase mind bomb-1. Stem Cells 2010, 28:1060-1070.
191. Stafford M.R., Jackson H., Mayo-Wilson E., Morrison A.P., Kendall T. Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ 2013, 346:f185.
192. Stefansson H., Rujescu D., Cichon S., Pietiläinen O.P., Ingason A., Steinberg S., Fossdal R., Sigurdsson E., Sigmundsson T., Buizer-Voskamp J.E., Hansen T., Jakobsen K.D., Muglia P., Francks C., Matthews P.M., Gylfason A., Halldorsson B.V., Gudbjartsson D., Thorgeirsson T.E., Sigurdsson A., Jonasdottir A., Jonasdottir A., Bjornsson A., Mattiasdottir S., Blondal T., Haraldsson M., Magnusdottir B.B., Giegling I., Möller H.J., Hartmann A., Shianna K.V., Ge D., Need A.C., Crombie C., Fraser G., Walker N., Lonnqvist J., Suvisaari J., Tuulio-Henriksson A., Paunio T., Toulopoulou T., Bramon E., Di Forti M., Murray R., Ruggeri M., Vassos E., Tosato S., Walshe M., Li T., Vasilescu C., Mühleisen T.W., Wang A.G., Ullum H., Djurovic S., Melle I., Olesen J., Kiemeney L.A., Franke B., GROUP, Sabatti C., Freimer N.B., Gulcher J.R., Thorsteinsdottir U., Kong A., Andreassen O.A., Ophoff R.A., Georgi A., Rietschel M., Werge T., Petursson H., Goldstein D.B., Nöthen M.M., Peltonen L., Collier D.A., St Clair D., Stefansson K. Large recurrent microdeletions associated with schizophrenia. Nature 2008, 455:232-236.
193. Sullivan P.F. Questions about DISC1 as a genetic risk factor for schizophrenia. Mol. Psychiatry 2013, 18:1050-1052.
194. Szulwach K.E., Li X., Smrt R.D., Li Y., Luo Y., Lin L., Santistevan N.J., Li W., Zhao X., Jin P. Cross talk between microRNA and epigenetic regulation in adult neurogenesis. J. Cell Biol. 2010, 189:127-141.
195. Takagi T., Jin W., Taya K., Watanabe G., Mori K., Ishii S. Schnurri-2 mutant mice are hypersensitive to stress and hyperactive. Brain Res. 2006, 1108:88-97.
196. Takao K., Kobayashi K., Hagihara H., Ohira K., Shoji H., Hattori S., Koshimizu H., Umemori J., Toyama K., Nakamura H.K., Kuroiwa M., Maeda J., Atsuzawa K., Esaki K., Yamaguchi S., Furuya S., Takagi T., Walton N.M., Hayashi N., Suzuki H., Higuchi M., Usuda N., Suhara T., Nishi A., Matsumoto M., Ishii S., Miyakawa T. Deficiency of schnurri-2, an MHC enhancer binding protein, induces mild chronic inflammation in the brain and confers molecular, neuronal, and behavioral phenotypes related to schizophrenia. Neuropsychopharmacology 2013, 38:1409-1425.
197. Tarabeux J., Kebir O., Gauthier J., Hamdan F.F., Xiong L., Piton A., Spiegelman D., Henrion É., Millet B., S2D Team, Fathalli F., Joober R., Rapoport J.L., DeLisi L.E., Fombonne É., Mottron L., Forget-Dubois N., Boivin M., Michaud J.L., Drapeau P., Lafrenière R.G., Rouleau G.A., Krebs M.O. Rare mutations in N-methyl-d-aspartate glutamate receptors in autism spectrum disorders and schizophrenia. Transl. Psychiatry 2011, 1:e55.
198. Thomson P.A., Parla J.S., McRae A.F., Kramer M., Ramakrishnan K., Yao J., Soares D.C., McCarthy S., Morris S.W., Cardone L., Cass S., Ghiban E., Hennah W., Evans K.L., Rebolini D., Millar J.K., Harris S.E., Starr J.M., MacIntyre D.J., Generation Scotland, McIntosh A.M., Watson J.D., Deary I.J., Visscher P.M., Blackwood D.H., McCombie W.R., Porteous D.J. 708 Common and 2010 rare DISC1 locus variants identified in 1542 subjects: analysis for association with psychiatric disorder and cognitive traits. Mol. Psychiatry 2014, 19:668-675.
199. Thuault S.J., Malleret G., Constantinople C.M., Nicholls R., Chen I., Zhu J., Panteleyev A., Vronskaya S., Nolan M.F., Bruno R., Siegelbaum S.A., Kandel E.R. Prefrontal cortex HCN1 channels enable intrinsic persistent neural firing and executive memory function. J. Neurosci. 2013, 33:13583-13599.
200. Tomppo L., Hennah W., Lahermo P., Loukola A., Tuulio-Henriksson A., Suvisaari J., Partonen T., Ekelund J., Lönnqvist J., Peltonen L. Association between genes of Disrupted In Schizophrenia 1 (DISC1) interactors and schizophrenia supports the role of the DISC1 pathway in the etiology of major mental illnesses. Biol. Psychiatry 2009, 65:1055-1062.
201. Trifilieff P., Feng B., Urizar E., Winiger V., Ward R.D., Taylor K.M., Martinez D., Moore H., Balsam P.D., Simpson E.H., Javitch J.A. Increasing dopamine D2 receptor expression in the adult nucleus accumbens enhances motivation. Mol. Psychiatry 2013, 18:1025-1033.
202. Tsai G.E., Lin P.Y. Strategies to enhance N-methyl-d-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr. Pharm. Des. 2010, 16:522-537.
203. van den Buuse M., Wischhof L., Lee R.X., Martin S., Karl T. Neuregulin 1 hypomorphic mutant mice: enhanced baseline locomotor activity but normal psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation. Int. J. Neuropsychopharmacol. 2009, 12:1383-1393.
204. van Os J., Kapur S. Schizophrenia. Lancet 2009, 374:635-645.
205. van Os J., Kenis G., Rutten B.P. The environment and schizophrenia. Nature 2010, 468:203-212.
206. Vekovischeva O.Y., Zamanillo D., Echenko O., Seppälä T., Uusi-Oukari M., Honkanen A., Seeburg P.H., Sprengel R., Korpi E.R. Morphine-induced dependence and sensitization are altered in mice deficient in AMPA-type glutamate receptor-A subunits. J Neurosci. 2001, 21:4451-4459.
207. Veltman J.A., Brunner H.G. De novo mutations in human genetic disease. Nat. Rev. Genet. 2012, 13:565-575.
208. Vogt M.A., Elkin H., Pfeiffer N., Sprengel R., Gass P., Inta D. Impact of adolescent GluA1 AMPA receptor ablation in forebrain excitatory neurons on behavioural correlates of mood disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2014, 264:625-629.
209. Vuillermot S., Joodmardi E., Perlmann T., Ögren S.O., Feldon J., Meyer U. Prenatal immune activation interacts with genetic Nurr1 deficiency in the development of attentional impairments. J. Neurosci. 2012, 32:436-451.
210. Waddington J.L., Hennessy R.J., O'Tuathaigh C.M.P., Owoeye O., Russell V. Schizophrenia and the lifetime trajectory of psychotic illness: developmental neuroscience and pathobiology, redux. The Origins of Schizophrenia 2012, 3-21. Columbia University Press, New York. A.S. Brown, P.H. Patterson (Eds.).
211. Walters J.T., Rujescu D., Franke B., Giegling I., Vásquez A.A., Hargreaves A., Russo G., Morris D.W., Hoogman M., Da Costa A., Moskvina V., Fernández G., Gill M., Corvin A., O'Donovan M.C., Donohoe G., Owen M.J. The role of the major histocompatibility complex region in cognition and brain structure: a schizophrenia GWAS follow-up. Am. J. Psychiatry 2013, 170:877-885.
212. Whalley H.C., Papmeyer M., Romaniuk L., Sprooten E., Johnstone E.C., Hall J., Lawrie S.M., Evans K.L., Blumberg H.P., Sussmann J.E., McIntosh A.M. Impact of a microRNA MIR137 susceptibility variant on brain function in people at high genetic risk of schizophrenia or bipolar disorder. Neuropsychopharmacology 2012, 37:2720-2729.
213. Wiedholz L.M., Owens W.A., Horton R.E., Feyder M., Karlsson R.M., Hefner K., Sprengel R., Celikel T., Daws L.C., Holmes A. Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and schizophrenia-related behaviors. Mol. Psychiatry 2008, 13:631-640.
214. Winchester C.L., Pratt J.A., Morris B.J. Risk genes for schizophrenia: translational opportunities for drug discovery. Pharmacol. Ther. 2014, 143:34-50. 10.1016/j.pharmthera.2014.02.003.
215. Wray N.R., Pergadia M.L., Blackwood D.H., Penninx B.W., Gordon S.D., Nyholt D.R., Ripke S., MacIntyre D.J., McGhee K.A., Maclean A.W., Smit J.H., Hottenga J.J., Willemsen G., Middeldorp C.M., de Geus E.J., Lewis C.M., McGuffin P., Hickie I.B., van den Oord E.J., Liu J.Z., Macgregor S., McEvoy B.P., Byrne E.M., Medland S.E., Statham D.J., Henders A.K., Heath A.C., Montgomery G.W., Martin N.G., Boomsma D.I., Madden P.A., Sullivan P.F. Genome-wide association study of major depressive disorder: new results, meta-analysis, and lessons learned. Mol. Psychiatry 2012, 17:36-48.
216. Wright C., Turner J.A., Calhoun V.D., Perrone-Bizzozero N. Potential impact of miR-137 and its targets in schizophrenia. Front. Genet. 2013, 4:58.
217. Wu M.C., Kraft P., Epstein M.P., Taylor D.M., Chanock S.J., Hunter D.J., Lin X. Powerful SNP-set analysis for case-control genome-wide association studies. Am. J. Hum. Genet. 2010, 86:929-942.
218. Wu M.C., Lee S., Cai T., Li Y., Boehnke M., Lin X. Rare-variant association testing for sequencing data with the sequence kernel association test. Am. J. Hum. Genet. 2011, 89:82-93.
219. Yang F., Li X., Sharma M., Zarnegar M., Lim B., Sun Z. Androgen receptor specifically interacts with novel p21-activated kinase, PAK6. J. Biol. Chem. 2001, 276:15345-15353.
220. Young J.W., Light G.A., Marston H.M., Sharp T., Geyer M.A. The 5-choice continuous performance test: evidence for a translational test of vigilance for mice. PLoS ONE 2009, 4:e4227.
221. Zhang C., Milunsky J.M., Newton S., Ko J., Zhao G., Maher T.A., Tager-Flusberg H., Bolliger M.F., Carter A.S., Boucard A.A., Powell C.M., Südhof T.C. A neuroligin-4 missense mutation associated with autism impairs neuroligin-4 folding and endoplasmic reticulum export. J. Neurosci. 2009, 29:10843-10854.
222. Zuccotti A., Clementi S., Reinbothe T., Torrente A., Vandael D.H., Pirone A. Structural and functional differences between L-type calcium channels: crucial issues for future selective targeting. Trends Pharmacol. Sci. 2011, 32:366-375.
223. Zuk O., Hechter E., Sunyaev S.R., Lander E.S. The mystery of missing heritability: genetic interactions create phantom heritability. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:1193-1198.